We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > INT41

News List

Vybion Receives Orphan Drug Designation for INT41 in Huntington's Disease firstwordpharma
December 04, 2018
Vybion Inc., a leading Gene Therapy Company developing Intrabodies to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for INT41, the Company's Intrabody deliver
Vybion Receives Orphan Drug Designation for INT41 in Huntington's Disease firstwordpharma
December 04, 2018
Vybion Inc., a leading Gene Therapy Company developing Intrabodies to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for INT41, the Company's Intrabody deliver